Keyword search (4,163 papers available)

"Masellis M" Authored Publications:

Title Authors PubMed ID
1 Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; 39893139
CONCORDIA
2 Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; 39636028
HKAP
3 Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab Chertkow H; Rockwood K; Hogan DB; Phillips N; Montero-Odasso M; Amanullah S; Black S; Bocti C; Borrie M; Feldman H; Freedman M; Hsiung R; Kirk A; Masellis M; Nygaard H; Rajji T; Verret L; 34912492
PSYCHOLOGY
4 Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study. Pieruccini-Faria F, Black SE, Masellis M, Smith EE, Almeida QJ, Li KZH, Bherer L, Camicioli R, Montero-Odasso M 33590967
PSYCHOLOGY
5 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; 33532543
PERFORM
6 The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ 31309917
PSYCHOLOGY

 

Title:Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.
Authors:Pieruccini-Faria FBlack SEMasellis MSmith EEAlmeida QJLi KZHBherer LCamicioli RMontero-Odasso M
Link:https://www.ncbi.nlm.nih.gov/pubmed/33590967
DOI:10.1002/alz.12298
Publication:Alzheimer' s & dementia : the journal of the Alzheimer' s Association
Keywords:biomarkercognitiondementiagait variabilityneurodegenerative diseases
PMID:33590967 Category:Alzheimers Dement Date Added:2021-02-17
Dept Affiliation: PSYCHOLOGY
1 Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada.
2 Schulich School of Medicine & Dentistry, Department of Medicine and Division of Geriatric Medicine, London, Ontario, Canada.
3 Schulich School of Medicine and Dentistry, Department of Epidemiology and Biostatistics, University of Western Ontario, London, N6C 0A7, Canada.
4 Department of Medicine and Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
5 Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
6 Movement Disorders Research & Rehabilitation Centre, Wilfrid Laurier University, Waterloo, Ontario, Canada.
7 Department of Psychology, Concordia University, Montreal, Quebec, Canada.
8 Departments of Medicine, Montreal Heart Institute and Institut Universitaire de Gériatrie de Montréal, University of Montreal, Montreal, Quebec, Canada.
9 Department of Medicine, Division of Neurology and Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.

Description:

Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.

Alzheimers Dement. 2021 Feb 16; :

Authors: Pieruccini-Faria F, Black SE, Masellis M, Smith EE, Almeida QJ, Li KZH, Bherer L, Camicioli R, Montero-Odasso M

Abstract

INTRODUCTION: Gait impairment is common in neurodegenerative disorders. Specifically, gait variability-the stride-to-stride fluctuations in distance and time-has been associated with neurodegeneration and cognitive impairment. However, quantitative comparisons of gait impairments across the cognitive spectrum of dementias have not been systematically investigated.

METHODS: Older adults (N = 500) with subjective cognitive impairment, Parkinson disease (PD), mild cognitive impairment (MCI), PD-MCI, Alzheimer's disease (AD), PD-dementia, Lewy body dementia, and frontotemporal dementia, as well cognitive normal controls, who were assessed for their gait and cognitive performance.

RESULTS: Factor analyses grouped 11 quantitative gait parameters and identified four independent gait domains: rhythm, pace, variability, and postural control, for group comparisons and classification analysis. Among these domains, only high gait variability was associated with lower cognitive performance and accurately discriminated AD from other neurodegenerative and cognitive conditions.

DISCUSSION: Our findings indicate that high gait variability is a marker of cognitive-cortical dysfunction, which can help to identify Alzheimer's disease dementia.

PMID: 33590967 [PubMed - as supplied by publisher]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University